GLP-1 Drugs Slash Heart Attack Risk: What the 90,000-Patient Review Shows | Denver

New research confirms what many of us in obesity medicine have suspected for years — GLP-1 drugs do more than help people lose weight. They protect the heart.

—

A massive review of more than 90,000 participants across 11 major international clinical trials found that people taking GLP-1 receptor agonists had a significantly lower risk of heart attack, stroke, and cardiovascular death compared to placebo. The research was published in Cardiovascular Diabetology by researchers at Anglia Ruskin University.

Here’s what the data actually says — and why it matters for Dr. Lazarus’s patients in Colorado.

The Numbers: 13% Reduction in Major Cardiovascular Events

Across trials averaging nearly three years of follow-up, GLP-1 drugs reduced major adverse cardiovascular events (MACE) by about 13%. That includes:

• Heart attack (non-fatal and fatal)
• Stroke (non-fatal and fatal)
• Cardiovascular death

But it doesn’t stop there. People taking these medications were also less likely to die from any cause during the study period. Hospitalizations for heart failure dropped too.

The benefits were consistent regardless of whether patients had type 2 diabetes — meaning the heart protection isn’t just a byproduct of better blood sugar control.

Who Benefits Most

The strongest cardiovascular benefits were seen in patients already at high risk: those with obesity, type 2 diabetes, or established heart disease. This describes a large proportion of the patients Dr. Lazarus sees in his Greenwood Village practice.

Colorado has high rates of cardiovascular disease statewide. Our active population isn’t immune — obesity and diabetes run parallel to heart risk even in people who exercise regularly. For these patients, a medication that moves both weight and heart risk in the right direction is significant.

What This Means in Practice

As an obesity medicine physician, I’ve watched GLP-1 medications prove themselves over and over. The weight loss data was compelling. The diabetes control data was compelling. Now we have three years of cardiovascular outcome data confirming what the mechanistic biology suggested: these drugs are doing something fundamental to cardiometabolic risk.

If you’re already on a GLP-1 medication and you have cardiovascular risk factors — high blood pressure, elevated cholesterol, a family history of heart disease, or simply obesity with a high BMI — this data reinforces that staying on your medication is doing more than helping you lose weight. It’s reducing your risk of the events that most threaten your life.

The review found no meaningful increase in serious safety risks (severe hypoglycemia or acute pancreatitis) compared to placebo. Gastrointestinal side effects like nausea and vomiting were more common — but that’s the known tolerability profile we already manage in clinic.

Clinical Takeaway

If you have obesity, type 2 diabetes, or existing cardiovascular disease and you haven’t discussed GLP-1 therapy with your physician, this data is another reason to have that conversation. The heart protection builds over time — averaging nearly three years of monitoring in this review — and appears to be independent of diabetes status.

For patients already on these medications: this is validation, not a reason to stop. Keep taking your medication as prescribed. The benefits compound with consistency.

—

Source: Anglia Ruskin University researchers, Cardiovascular Diabetology. Review of 11 major international trials, 90,000+ participants, average follow-up nearly 3 years. GLP-1 receptor agonists studied included semaglutide, liraglutide, and dulaglutide.